分析
2026年9月18日•1分で読めます
Mirae Asset Report Shows Korean Pharma & Bio Firms Strengthening Fundamentals Amid Market Weakness
Despite short‑term stock pressure from interest rates and supply issues, Korean pharma and biotech companies are pursuing M&A, tech exports and capacity investments, boosting fundamentals, says a Mirae Asset report.
分析
2026年8月30日•1分で読めます
High Won Exchange Rate Affects Pharma & Bio Companies Differently
While a weak won usually boosts exporters, pharma and biotech firms see mixed effects as foreign revenue growth is offset by rising foreign‑currency costs for raw materials, debt and liabilities.
分析
2026年8月27日•1分で読めます
Klick Health Acquires Oxford PharmaGenesis in Third Takeover Within 18 Months
Klick Health completes its third acquisition in 18 months, buying Oxford PharmaGenesis to expand globally and deepen scientific expertise.